Ten years of leptin replacement therapy
G Paz-Filho1, M-L Wong, J Licinio
1Department of Translational Medicine, John Curtin School of Medicine, The Australian National University, Canberra, Australia.
Summary
Congenital leptin deficiency in humans reveals leptin
Area of Science:
- Endocrinology
- Neuroscience
- Metabolism
Background:
- Leptin, a pleiotropic hormone, regulates energy balance, neuroendocrine function, immunity, and metabolism.
- Congenital leptin deficiency in humans offers a unique model to study leptin's multifaceted roles.
Observation:
- Five Turkish patients with congenital leptin deficiency due to a leptin gene mutation were identified.
- Four patients received recombinant methionyl human leptin treatment, with comprehensive evaluations before and during therapy.
Findings:
- Leptin exerts peripheral, hypothalamic, and extra-hypothalamic effects.
- Leptin regulates circadian rhythms of cortisol, TSH, LH, and FSH.
- Leptin influences energy balance, body weight, neurogenesis, brain function, immune response, inflammation, coagulation, and platelet aggregation.
Implications:
- Leptin is crucial for endocrine, neural, metabolic, and immune system regulation.
- This 10-year study provides valuable insights into leptin's central and peripheral actions.
- Findings may inform the development of leptin-based therapies for various diseases.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...